Antibody Production, Longevity and Safety Outcomes of Two Anti-SARS-CoV-2 Vaccines, Covaxin and Covishield
RUHS Journal of Health Science · 2025
DOI: 10.37821/ruhsjhs.10.1.2025.702 ↗Kurz gefasst
Fachartikel in der Zeitschrift RUHS Journal of Health Science, 2025. Verfasst von Susheel Kumar Jain und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
In India, Covaxin and Covishield were approved under restricted emergency use for vaccination of its healthcare and frontline workers against SARS-CoV-2, in January, 2021. Variety of factors like, environmental factors, vaccine storage and transportation, individual’s response to vaccine governed by sex, age, genetic factors, nutritional status, comorbidities etc are likely to have an impact on vaccine efficiency. The study was conducted to assess antibody production, longevity and safety outcomes of these two vaccines among healthcare workers in the age group of 18 to 65 years. Methodology: The study participants were followed and their antibody (Ab) titres against spike antigen of SARS-CoV-2 were noted before vaccination, one month after first and second dose and were further followed at 3 months-interval over a period of one year along with the adverse effects profile due to vaccination. Total 418 participants were divided into three groups, 135 were in control group, 142 in group 1 (received two doses of CovaxinTM) and 141 in group 2 (received two doses of CovishieldTM). Humoral responses were assessed using a standardised total IgG response against spike receptor binding domain (RBD) by chemiluminiscence immunoassay (CLIA) based Advia Centaur SARS-CoV-2 by Siemens.
Results
Pain at the site of injection was the commonest symptom post vaccination. Higher proportion of participants with >20 titres was found in previously COVID-19 positive participants i.e. 88.6% (62/ 70) in group 2, followed by previously COVID-19 negative participants in the same group i.e. 56.3% (40/71).
Conclusion
Both vaccines were very well tolerated, induced good humoral response against SARS-CoV-2 and can contribute well in control measures against COVID-19. Covishield may induce a slightly stronger immune response, resulting in higher antibody levels.
Zitieren
APA
Jain, S. K., Jain, D. K., Batra, S., Sharma, M., Sinha, P., Dhenwal, N., Vyas, N., & Maheshwari, R. (2025). Antibody Production, Longevity and Safety Outcomes of Two Anti-SARS-CoV-2 Vaccines, Covaxin and Covishield. RUHS Journal of Health Science. https://doi.org/10.37821/ruhsjhs.10.1.2025.702
Vancouver
Jain SK, Jain DK, Batra S, Sharma M, Sinha P, Dhenwal N, et al. Antibody Production, Longevity and Safety Outcomes of Two Anti-SARS-CoV-2 Vaccines, Covaxin and Covishield. RUHS Journal of Health Science. 2025. doi:10.37821/ruhsjhs.10.1.2025.702
BibTeX
@article{Jain2025,
author = {Jain, Susheel Kumar and Jain, Dinesh Kumar and Batra, Shivra and Sharma, Malvika and Sinha, Parul and Dhenwal, Nisha and Vyas, Nitya and Maheshwari, Rakesh},
title = {Antibody Production, Longevity and Safety Outcomes of Two Anti-SARS-CoV-2 Vaccines, Covaxin and Covishield},
journal = {RUHS Journal of Health Science},
year = {2025},
doi = {10.37821/ruhsjhs.10.1.2025.702}
}
EUVIMED